1. SWH Digital Repository

Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 17 (Search time: 0.004 seconds).
Item hits:
PreviewIssue DateTitle / NameAuthor(s)Type
31-May-2023Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia: ARORA Registry.Wen Lok, Sheau; Tung, Iris; Anton, Angelyn; Baron-Hay, Sally E.; De Boer, Richard H.; Boyle, Frances M.; Collins, Ian M.; Cuff, Katharine; Gately, Lucy; Georgiou, Chloe L.; Greenberg, Sally; Bhaskar, Karki; Nott, Louise M.; Nottage, Michelle K.; Rainey, Natalie; Torres, Javier; Yeo, Belinda Jane; Gibbs, Peter; Wong, Vanessa; Collins, Ian M.Conference Paper
Jan-2023Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancerLoft, Matthew; Lok, Sheau Wen; De Boer, Richard; Malik, Laeeq; Greenberg, Sally; Yeo, Belinda; Anton, Angelyn; Nottage, Michelle; Wong, Vanessa; Nott, Louise; Torres, Javier; Barnett, Frances; Lombard, Janine M.; Gibbs, Peter; Gately, Lucy; Collins, Ian M.; Collins, Ian M.Journal Article
2022CDK4/6 Inhibitors (CKD4/6i) in advanced hormone-receptor-positive (HR+) HER2-negative (HER2-) breast cancer: Prescribing practices and outcomes in a real-world, Australian cohortJavaid, Anadil; Lok, Sheau Wen; Wong, Vanessa; Baron-Hay, Sally; Boyle, Fran; Collins, Ian M.; Cuff, Katharine; De Boer, Richard; Gately, Lucy; Georgiou, Chloe; Greenberg, Sally; Karki, Bhaskar; Nottage, Michelle; Rainey, Natalie; Torres, Javier; Yeo, Belinda; Devitt, Bianca; Gibbs, Peter; Anton, Angelyn; Collins, Ian M.Conference Paper
2021Uptake of bone-modifying agents in patients with HER2+ metastatic breast cancer with bone metastases - prospective data from a multi-site Australian registryWong, Vanessa; de Boer, Richard; Dunn, Catherine; Anton, Angelyn; Malik, Laeeq; Greenberg, Sally; Yeo, Belinda; Nott, Louise; Collins, Ian M.; Torres, Javier; Barnett, Frances; Nottage, Michelle; Gibbs, Peter; Lok, Sheau Wen; Collins, Ian M.Journal Article
2020Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancerLoft, Matthew; Lok, Sheau Wen; De Boer, Richard H.; Malik, Laeeq; Greenberg, Sally; Yeo, Belinda; Anton, Angelyn; Nott, Louise M.; Richardson, Gary Edward; Collins, Ian M.; Torres, Javier; Barnett, Frances Sarah; Devitt, Bianca Alix; Gibbs, Peter; Gately, Lucy; Collins, Ian M.Journal Article
Annals of Oncology - 2020 - Real World Outcomes in Elderly Women with HER2-Positive Advanced Breast Cancer.pdf.jpg2020Real World Outcomes in Elderly Women with HER2-Positive Advanced Breast CancerEvans, Nicole; Anton, Angelyn; Wong, Rachel; Lok, Sheau Wen; De Boer, Richard; Malik, Laeeq; Greenberg, Sally; Yeo, Belinda; Nott, Louise; Richardson, Gary; Collins, Ian M.; Torres, Javier; Barnett, Frances; Gibbs, Peter; Devitt, Bianca; Collins, Ian M.Conference Paper
2020Real-world uptake of bone modifying agents in advanced breast cancer with bone metastases-Prospective data from a multi-site Australian registryWong, Vanessa; De Boer, Richard; Anton, Angelyn; Malik, Laeeq; Greenberg, Sally; Yeo, Belinda; Nott, Louise W.; Collins, Ian M.; Torres, Javier; Barnett, Frances; Gibbs, Peter; Lok, Sheau Wen; Collins, Ian M.Conference Paper
2020Real-world impact of anti-HER2 therapy-related cardiotoxicity in patients with advanced HER2-positive breast cancerConduit, C.; de Boer, R. H.; Lok, S.; Gibbs, Peter; Malik, Laeeq; Loh, Z.; Yeo, Belinda; Greenberg, Sally; Devitt, Bianca; Lombard, Janine; Nottage, Michelle; Collins, Ian M.; Torres, Javier; Nolan, M.; Nott, Louise; Collins, Ian M.Journal Article
2020Real world outcomes in elderly patients with HER2 positive advanced breast cancerEvans, Nicole; Anton, Angelyn; Wong, Rachel; Lok, Sheau Wen; De Boer, Richard; Malik, Laeeq; Greenberg, Sally; Yeo, Belinda; Nott, Louise; Richardson, Gary; Collins, Ian M.; Torres, Javier; Barnett, Frances; Gibbs, Peter; Devitt, Bianca; Collins, Ian M.Conference Paper
PLOS ONE - 2019 - Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.pdf.jpg2019Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of responseMurphy, Caitlin; Muscat, Andrea; Ashley, David; Mukaro, Violet; West, Linda; Liao, Yang; Chisanga, David; Shi, Wei; Collins, Ian M.; Baron-Hay, Sally; Patil, Sujata; Lindeman, Geoffrey; Khasraw, Mustafa; Collins, Ian M.Journal Article

Discover